- Home
- ONTF vs DRUG Comparison
ONTF vs DRUG Comparison
Compare ONTF & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTF
- DRUG
- Stock Information
- Founded
- ONTF 1998
- DRUG 2019
- Country
- ONTF United States
- DRUG United States
- Employees
- ONTF N/A
- DRUG N/A
- Industry
- ONTF Computer Software: Prepackaged Software
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ONTF Technology
- DRUG Health Care
- Exchange
- ONTF Nasdaq
- DRUG Nasdaq
- Market Cap
- ONTF 221.7M
- DRUG 199.7M
- IPO Year
- ONTF 2021
- DRUG N/A
- Fundamental
- Price
- ONTF $5.49
- DRUG $24.42
- Analyst Decision
- ONTF Hold
- DRUG Strong Buy
- Analyst Count
- ONTF 4
- DRUG 6
- Target Price
- ONTF $5.33
- DRUG $83.25
- AVG Volume (30 Days)
- ONTF 253.1K
- DRUG 53.2K
- Earning Date
- ONTF 08-05-2025
- DRUG 08-13-2025
- Dividend Yield
- ONTF N/A
- DRUG N/A
- EPS Growth
- ONTF N/A
- DRUG N/A
- EPS
- ONTF N/A
- DRUG N/A
- Revenue
- ONTF $145,087,000.00
- DRUG N/A
- Revenue This Year
- ONTF N/A
- DRUG N/A
- Revenue Next Year
- ONTF N/A
- DRUG N/A
- P/E Ratio
- ONTF N/A
- DRUG N/A
- Revenue Growth
- ONTF N/A
- DRUG N/A
- 52 Week Low
- ONTF $4.35
- DRUG $0.93
- 52 Week High
- ONTF $7.04
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ONTF 53.83
- DRUG 34.00
- Support Level
- ONTF $5.21
- DRUG $26.00
- Resistance Level
- ONTF $5.45
- DRUG $28.49
- Average True Range (ATR)
- ONTF 0.15
- DRUG 1.53
- MACD
- ONTF -0.02
- DRUG -0.10
- Stochastic Oscillator
- ONTF 50.00
- DRUG 14.58
About ONTF ON24 Inc.
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The Company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.